Multiple myeloma treatment strategies have also evolved with the emergence of new therapies with novel mechanisms of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets. Bispecifics have been another strategy with the presence of TECVAYLI in the market for multiple myeloma. Trispecifics are the newly introduced approach. 

Johnson & Johnson Innovative Medicine has presented the data of JNJ-79635322 (JNJ-5322), a next-generation trispecific antibody at EHA 2025. The most common adverse event was Cytokine Release Syndrome (CRS), occurring in 59% of patients, but no events were Grade 3 or higher. Twenty-eight percent of patients experienced Grade 3 or higher infections. Five patients had dose-limiting toxicities, and four treatment-emergent patient deaths due to adverse events were reported, with one death caused by adenoviral encephalitis related to the drug. Taste-related AEs were reported in 58% of patients, the majority Grade 1. The incidence of other GPRC5D-related oral AEs was low, with dry mouth reported in 17 percent of patients and dysphagia reported in less than 4% of patients. In addition, Grade 1/2 weight loss occurred in 6% (Recommended Phase II Dose) and 12% (all doses) of patients, with no Grade ≥3 weight loss events.

KOL insights

“The response rate with JNJ-5322 is encouraging as we explore the potential of this trispecific antibody for the treatment of relapsed or refractory multiple myeloma patients.” – Expert Opinion

Conclusion

Immunotherapy is a promising and innovative approach to myeloma treatment. It involves using monoclonal antibodies, CAR-T cells, or bispecific antibodies to boost the immune system’s ability to fight cancer cells. These therapies have shown remarkable results in patients who have failed other treatments. However, there is still room for improvement, as some responses are not lasting. This raises the possibility of using immunotherapy earlier in the disease course, such as at first relapse or even as initial therapy. This could potentially improve the outcomes and quality of life of myeloma patients and create new opportunities for the market. The approval of trispecific antibodies in the market of multiple myeloma will be a boon to the treatment pattern. 

Trispecific antibodies have emerged as a promising new frontier in multiple myeloma treatment. The obtained promising data of JNJ-79635322 can be a major step forward as Johnson & Johnson works to transform outcomes in oncology with next-generation immunotherapies, building on our leading portfolio of complementary and combinable therapies. The company looks forward to seeing the results of planned Phase II and Phase III studies. Other TsAbs evaluated in multiple myeloma include ISB 2001, SAR442257, and others.